Autor(es):
Ferreira, J. 
; Almeida, I. ; Marinho, A. ; Cerveira, C. ; Vasconcelos, C.
Data: 2012
Identificador Persistente: http://hdl.handle.net/10400.16/905
Origem: Repositório Científico do Centro Hospitalar do Porto
Descrição
The presence of anti-Ro52 antibodies has been reported in a wide variety of autoimmune diseases, particularly in
myositis, scleroderma, and autoimmune liver diseases. Clinical significance of anti-Ro52 antibodies remains controversial, and
studies are lacking for clarifying the association of anti-Ro52 with interstitial lung disease (ILD) in connective tissue diseases
(CTD). Objectives. To determine if anti-Ro52 antibodies are associated with ILD in CTD other than scleroderma. Methods. Singlecenter,
retrospective study based on immunoblotting panel analysis and patients clinical records. Results. In our connective tissue
disease cohort, 162 patients had immunoblotting panels with anti-Ro52 reactivity analysis, 41 (25,3%) had inclusion criteria.
Among the 41 selected sera, 85.4% (n = 35) had anti-Ro52 reactivity. The prevalence of ILD in the positive anti-Ro52 antibodies
was 71.4% (n = 25), and 16.7% (n = 1) in the negative anti-Ro52 group (P = 0.018). Overall sensitivity (96.2%), specificity
(83.3%), positive (71.4%) and negative (83.3%) predictive values of anti-Ro52 antibodies to determine ILD in CTD is detailed in
this study. Conclusion. Ro52 autoantibodies are associated with ILD in CTD excluding scleroderma. We suggest that the presence
of anti-Ro52 reactivity in CTD should increase the clinician curiosity for the search of ILD.
